Lung Cancer Therapy Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Therapy Type (Noninvasive and Minimally Invasive), Indication (Non-Small Cell Lung Cancer and Small Cell Lung Cancer), End User (Hospitals, Oncology Clinics, Research Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
The lung cancer therapy market is expected to grow from US$ 31.018 billion in 2022 to US$ 80.493 billion by 2030; it is anticipated to record a CAGR of 12.7% from 2022 to 2030.
Targeted therapy, a type of personalized medicine, is a combination of two or more drugs, designed to directly target the cancerous cells. Therapies such as ablation and chemotherapy destroy healthy cells along with infected cells, which can affect the overall patient condition. Targeted therapy is designed in a way to selectively kill cancerous cells, keeping the function of healthy cells unhampered. With recent developments in medical technologies, focus on the use of targeted therapy for the treatment of lung cancer is increasing notably. Scientists are focusing on studying lung cancer cell mutations that are responsible for driving the uncontrolled growth of cancerous cells. In May 2021, the US Food and Drug Administration approved Lumakras (sotorasib), the first treatment for adult non-small cell lung cancer patients. This therapy is given to patients who have KRAS G12C mutation and have received at least one prior systemic therapy. The companies are using biomarkers such as EGFR, ALK, ROS1, and KRAS to develop targeted therapies, which help detect the type of mutation in the cancerous cells. Thus, the increasing focus of companies on the development of targeted therapies, coupled with the growing awareness about their benefits to lung cancer patients, is expected to bring new trends in the lung cancer therapy market in the coming years.
Government Initiatives for Screening and Treatment of Lung Cancer drives the growth the Lung Cancer Therapy Market
According to an article published by Johnson & Johnson, lung cancer is a leading cause of cancer mortality in the world, and it is generally detected in the later stages. In the initial stages, people with lung cancer show no prominent symptoms, and therefore, in almost 50% of the detected cases, cancer has already reached the metastasis stage. In response to the seriousness of this condition, governments of various countries are focusing on introducing initiatives for encouraging early detection and screening, followed by providing early treatment for lung cancer.
As per United States Preventive Services Task Force (USPSTF), people from the age range of 50–80 with a smoking history of 20 packs per year, either presently smoking or having quit within the last 15 years, are more susceptible to developing lung cancer in the US. Hence, the United States Preventive Services Task Force (USPSTF) recommends these people undergo low-dose computed tomography (LDCT) screening for lung cancer every year to ensure the early detection of lung cancer. In addition, in July 2022, the Biden Administration in the US introduced a new model that aims to improve cancer care and lower the treatment cost for patients who are covered under Medicare services.
In July 2021, Cancer Australia partnered with the Department of Health and Aged Care to evaluate the feasibility of a lung cancer screening program in Australia. After obtaining positive results of the feasibility assessment, in May 2023, the Department of Health and Aged Care, the Government of Australia, declared an investment of US$ 263.8 million for 2023–2024 for the implementation of the National Lung Cancer Screening Program across the country. Through this program, the Department of Health and Aged Care focuses on the prevention and early detection of lung cancer. Further, the Beating Cancer Plan introduced by the European Health Union aims to tackle the entire disease pathway by focusing on prevention, treatment, and care of lung cancer patients.
Thus, an upsurge in initiatives taken by governments for the early detection and proper treatment of lung cancer patients fuels the growth of the lung cancer therapy market.
The lung cancer therapy market is divided on the basis of therapy type, indication, end user, and geography. The lung cancer therapy market, by vaccine type, is bifurcated into noninvasive and minimally invasive. The minimally invasive segment is further classified into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others. The lung cancer therapy market, by indication, is segmented into non-small cell lung cancer and small cell lung cancer. The market, by end user, is segmented into hospitals, oncology clinics, research centers, and others.
Based on geography, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share of the lung cancer therapy market. North America accounts for a significant market share owing to the growing incidences of lung cancer cases due to increase in smoking, consumption of tobacco, and increase in air pollution due to industrialization. The growth of the lung cancer therapy market in the US is mainly driven by the increasing incidence of lung cancer cases, product launches, and government initiatives. Lung cancer is the second most common cancer in the US. As per the American Cancer Society, Inc., as of 2023, ~238,340 adults (117,550 men and 120,790 women) in the US have been diagnosed with lung cancer; also, ~127,070 (67,160 in men and 59,910 in women) have succumbed to death due to the disease. Lung cancer accounts for 1 in 5 of all cancer deaths, making it a leading cause of cancer death in the US. As per the same source, NSCLC accounts for 81% of all lung cancer diagnoses. Thus, the increasing incidence of lung cancer in the country fuels the growth of the US lung cancer therapy market.
Various product launches for the treatment of lung cancer by companies are also bolstering the market growth. For instance, in May 2021, the US FDA approved Lumakras (sotorasib) as the first targeted therapy for adult non-small cell lung cancer patients. This is the first targeted therapy that is approved for tumors with KRAS mutation, which reports ~25% of mutations in non-small cell lung cancer (NSCLC). Moreover, in May 2021, the US FDA granted accelerated approval to amivantamab-vmjw (Rybrevant), a bispecific antibody directed against epidermal growth factor (EGF) and MET receptors, for adult patients with locally advanced or metastatic NSCLC that comprises EGFR exon 20 insertion mutations.
As per the report published in the whitehouse.gov, the official website of the White House, managed by the Office of Digital Strategy in May 2023, the Association of Community Cancer Centers (ACCC) and AstraZeneca entered into a partnership for the development and implementation of person-centered and sustainable approaches to drive lung cancer screening in rural America through “Rural Appalachian Lung Cancer Screening Initiative.” The cancer mortality rate in the Appalachian region, including all of West Virginia and a few parts of 12 other states, is 10% higher than that of the rest of the US. This initiative aims to double the five-year survival rate for lung cancer. Such initiatives are contributing to the growth of the lung cancer therapy market in the US.
ClinicalTrails.com, Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and United States Preventive Services Task Force (USPSTF) are a few key primary and secondary sources referred to while preparing the report on the lung cancer therapy market.
Targeted therapy, a type of personalized medicine, is a combination of two or more drugs, designed to directly target the cancerous cells. Therapies such as ablation and chemotherapy destroy healthy cells along with infected cells, which can affect the overall patient condition. Targeted therapy is designed in a way to selectively kill cancerous cells, keeping the function of healthy cells unhampered. With recent developments in medical technologies, focus on the use of targeted therapy for the treatment of lung cancer is increasing notably. Scientists are focusing on studying lung cancer cell mutations that are responsible for driving the uncontrolled growth of cancerous cells. In May 2021, the US Food and Drug Administration approved Lumakras (sotorasib), the first treatment for adult non-small cell lung cancer patients. This therapy is given to patients who have KRAS G12C mutation and have received at least one prior systemic therapy. The companies are using biomarkers such as EGFR, ALK, ROS1, and KRAS to develop targeted therapies, which help detect the type of mutation in the cancerous cells. Thus, the increasing focus of companies on the development of targeted therapies, coupled with the growing awareness about their benefits to lung cancer patients, is expected to bring new trends in the lung cancer therapy market in the coming years.
Government Initiatives for Screening and Treatment of Lung Cancer drives the growth the Lung Cancer Therapy Market
According to an article published by Johnson & Johnson, lung cancer is a leading cause of cancer mortality in the world, and it is generally detected in the later stages. In the initial stages, people with lung cancer show no prominent symptoms, and therefore, in almost 50% of the detected cases, cancer has already reached the metastasis stage. In response to the seriousness of this condition, governments of various countries are focusing on introducing initiatives for encouraging early detection and screening, followed by providing early treatment for lung cancer.
As per United States Preventive Services Task Force (USPSTF), people from the age range of 50–80 with a smoking history of 20 packs per year, either presently smoking or having quit within the last 15 years, are more susceptible to developing lung cancer in the US. Hence, the United States Preventive Services Task Force (USPSTF) recommends these people undergo low-dose computed tomography (LDCT) screening for lung cancer every year to ensure the early detection of lung cancer. In addition, in July 2022, the Biden Administration in the US introduced a new model that aims to improve cancer care and lower the treatment cost for patients who are covered under Medicare services.
In July 2021, Cancer Australia partnered with the Department of Health and Aged Care to evaluate the feasibility of a lung cancer screening program in Australia. After obtaining positive results of the feasibility assessment, in May 2023, the Department of Health and Aged Care, the Government of Australia, declared an investment of US$ 263.8 million for 2023–2024 for the implementation of the National Lung Cancer Screening Program across the country. Through this program, the Department of Health and Aged Care focuses on the prevention and early detection of lung cancer. Further, the Beating Cancer Plan introduced by the European Health Union aims to tackle the entire disease pathway by focusing on prevention, treatment, and care of lung cancer patients.
Thus, an upsurge in initiatives taken by governments for the early detection and proper treatment of lung cancer patients fuels the growth of the lung cancer therapy market.
The lung cancer therapy market is divided on the basis of therapy type, indication, end user, and geography. The lung cancer therapy market, by vaccine type, is bifurcated into noninvasive and minimally invasive. The minimally invasive segment is further classified into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others. The lung cancer therapy market, by indication, is segmented into non-small cell lung cancer and small cell lung cancer. The market, by end user, is segmented into hospitals, oncology clinics, research centers, and others.
Based on geography, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share of the lung cancer therapy market. North America accounts for a significant market share owing to the growing incidences of lung cancer cases due to increase in smoking, consumption of tobacco, and increase in air pollution due to industrialization. The growth of the lung cancer therapy market in the US is mainly driven by the increasing incidence of lung cancer cases, product launches, and government initiatives. Lung cancer is the second most common cancer in the US. As per the American Cancer Society, Inc., as of 2023, ~238,340 adults (117,550 men and 120,790 women) in the US have been diagnosed with lung cancer; also, ~127,070 (67,160 in men and 59,910 in women) have succumbed to death due to the disease. Lung cancer accounts for 1 in 5 of all cancer deaths, making it a leading cause of cancer death in the US. As per the same source, NSCLC accounts for 81% of all lung cancer diagnoses. Thus, the increasing incidence of lung cancer in the country fuels the growth of the US lung cancer therapy market.
Various product launches for the treatment of lung cancer by companies are also bolstering the market growth. For instance, in May 2021, the US FDA approved Lumakras (sotorasib) as the first targeted therapy for adult non-small cell lung cancer patients. This is the first targeted therapy that is approved for tumors with KRAS mutation, which reports ~25% of mutations in non-small cell lung cancer (NSCLC). Moreover, in May 2021, the US FDA granted accelerated approval to amivantamab-vmjw (Rybrevant), a bispecific antibody directed against epidermal growth factor (EGF) and MET receptors, for adult patients with locally advanced or metastatic NSCLC that comprises EGFR exon 20 insertion mutations.
As per the report published in the whitehouse.gov, the official website of the White House, managed by the Office of Digital Strategy in May 2023, the Association of Community Cancer Centers (ACCC) and AstraZeneca entered into a partnership for the development and implementation of person-centered and sustainable approaches to drive lung cancer screening in rural America through “Rural Appalachian Lung Cancer Screening Initiative.” The cancer mortality rate in the Appalachian region, including all of West Virginia and a few parts of 12 other states, is 10% higher than that of the rest of the US. This initiative aims to double the five-year survival rate for lung cancer. Such initiatives are contributing to the growth of the lung cancer therapy market in the US.
ClinicalTrails.com, Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and United States Preventive Services Task Force (USPSTF) are a few key primary and secondary sources referred to while preparing the report on the lung cancer therapy market.
1. INTRODUCTION
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Lung Cancer Therapy Market, by Geography
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. LUNG CANCER THERAPY MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.2.1 Global PEST Analysis
5. LUNG CANCER THERAPY MARKET - KEY INDUSTRY DYNAMICS
5.1 Market Drivers:
5.1.1 Increase in Cases of Lung Cancer
5.1.2 Government Initiatives for Screening and Treatment of Lung Cancer
5.2 Market Restraints
5.2.1 High Cost of Lung Cancer Therapy
5.3 Market Opportunities
5.3.1 Rising Number of Lung Cancer Therapy in Clinical Trials
5.4 Future Trends
5.4.1 Growing Demand for Targeted Therapy
5.5 Impact Analysis:
6. LUNG CANCER THERAPY MARKET - GLOBAL MARKET ANALYSIS
6.1 Lung Cancer Therapy Market Revenue (US$ Mn), 2020 – 2030
7. GLOBAL LUNG CANCER THERAPY MARKET – REVENUE AND FORECAST TO 2030 – BY THERAPY TYPE
7.1 Overview
7.2 Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
7.3 Non-Invasive Therapy
7.3.1 Overview
7.3.2 Non-Invasive Therapy: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Minimally Invasive
7.4.1 Overview
7.4.2 Minimally Invasive: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
7.4.2.1 Global: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
8. GLOBAL LUNG CANCER THERAPY MARKET – REVENUE AND FORECAST TO 2030 – BY INDICATION
8.1 Overview
8.2 Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Non-Small Cell Lung Cancer
8.3.1 Overview
8.3.2 Non-Small Cell Lung Cancer: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Small Cell Lung Cancer
8.4.1 Overview
8.4.2 Small Cell Lung Cancer: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9. GLOBAL LUNG CANCER THERAPY MARKET – REVENUE AND FORECAST TO 2030 – BY END USER
9.1 Overview
9.2 Lung Cancer Therapy Market Revenue Share, by End User, 2022 & 2030 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Oncology Clinics
9.4.1 Overview
9.4.2 Oncology Clinics: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Research Centers
9.5.1 Overview
9.5.2 Research Centers: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
10. LUNG CANCER THERAPY MARKET - GEOGRAPHICAL ANALYSIS
10.1 North America Lung Cancer Therapy Market, Revenue and Forecast To 2030
10.1.1 Overview
10.1.2 North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.3 North America: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.3.1 North America: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.1.4 North America: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.5 North America: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.1.6 North America Lung Cancer Therapy Market, by Country
10.1.6.1 US
10.1.6.1.1 Overview
10.1.6.1.2 US Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.1.3 US: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.6.1.3.1 US: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.1.6.1.4 US: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.6.1.5 US: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.1.6.2 Canada
10.1.6.2.1 Overview
10.1.6.2.2 Canada Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.2.3 Canada: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.6.2.3.1 Canada: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.1.6.2.4 Canada: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.6.2.5 Canada: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.1.6.3 Mexico
10.1.6.3.1 Overview
10.1.6.3.2 Mexico Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.3.3 Mexico: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.6.3.3.1 Mexico: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.1.6.3.4 Mexico: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.6.3.5 Mexico: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2 Europe Lung Cancer Therapy Market, Revenue and Forecast to 2030
10.2.1 Overview
10.2.2 Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.3 Europe: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.3.1 Europe: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.4 Europe: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.5 Europe: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6 Europe Lung Cancer Therapy Market, by Country
10.2.6.1 UK
10.2.6.1.1 Overview
10.2.6.1.2 UK Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.1.3 UK: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.1.3.1 UK: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.1.4 UK: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.1.5 UK: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.2 Germany
10.2.6.2.1 Overview
10.2.6.2.2 Germany Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.2.3 Germany: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.2.3.1 Germany: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.2.4 Germany: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.2.5 Germany: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.3 France
10.2.6.3.1 Overview
10.2.6.3.2 France Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.3.3 France: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.3.3.1 France: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.3.4 France: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.3.5 France: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.4 Italy
10.2.6.4.1 Overview
10.2.6.4.2 Italy Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.4.3 Italy: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.4.3.1 Italy: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.4.4 Italy: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.4.5 Italy: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.5 Spain
10.2.6.5.1 Overview
10.2.6.5.2 Spain Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.5.3 Spain: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.5.3.1 Spain: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.5.4 Spain: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.5.5 Spain: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.6 Russia
10.2.6.6.1 Overview
10.2.6.6.2 Russia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.6.3 Russia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.6.3.1 Russia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.6.4 Russia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.6.5 Russia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.7 Rest of Europe
10.2.6.7.1 Overview
10.2.6.7.2 Rest of Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.7.3 Rest of Europe: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.7.3.1 Rest of Europe: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.7.4 Rest of Europe: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.7.5 Rest of Europe: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3 Asia Pacific Lung Cancer Therapy Market, Revenue and Forecast to 2030
10.3.1 Overview
10.3.2 Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.3 Asia Pacific: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.3.1 Asia Pacific: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.4 Asia Pacific: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.5 Asia Pacific: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6 Asia Pacific Lung Cancer Therapy Market, by Country
10.3.6.1 China
10.3.6.1.1 Overview
10.3.6.1.2 China Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.1.3 China: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.1.3.1 China: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.1.4 China: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.1.5 China: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.2 Japan
10.3.6.2.1 Overview
10.3.6.2.2 Japan Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.2.3 Japan: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.2.3.1 Japan: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.2.4 Japan: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.2.5 Japan: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.3 India
10.3.6.3.1 Overview
10.3.6.3.2 India Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.3.3 India: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.3.3.1 India: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.3.4 India: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.3.5 India: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.4 Australia
10.3.6.4.1 Overview
10.3.6.4.2 Australia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.4.3 Australia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.4.3.1 Australia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.4.4 Australia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.4.5 Australia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.5 South Korea
10.3.6.5.1 Overview
10.3.6.5.2 South Korea Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.5.3 South Korea: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.5.3.1 South Korea: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.5.4 South Korea: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.5.5 South Korea: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6 Southeast Asia
10.3.6.6.1 Overview
10.3.6.6.2 Southeast Asia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.3 Southeast Asia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.3.1 Southeast Asia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.4 Southeast Asia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.5 Southeast Asia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.6 Singapore
10.3.6.6.6.1 Singapore Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.6.2 Singapore: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.6.2.1 Singapore: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.6.3 Singapore: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.6.4 Singapore: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.7 Malaysia
10.3.6.6.7.1 Malaysia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.7.2 Malaysia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.7.2.1 Malaysia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.7.3 Malaysia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.7.4 Malaysia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.8 Indonesia
10.3.6.6.8.1 Indonesia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.8.2 Indonesia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.8.2.1 Indonesia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.8.3 Indonesia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.8.4 Indonesia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.9 Vietnam
10.3.6.6.9.1 Vietnam Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.9.2 Vietnam: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.9.2.1 Vietnam: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.9.3 Vietnam: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.9.4 Vietnam: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.10 Cambodia
10.3.6.6.10.1 Cambodia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.10.2 Cambodia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.10.2.1 Cambodia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.10.3 Cambodia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.10.4 Cambodia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.11 Philippines
10.3.6.6.11.1 Philippines Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.11.2 Philippines: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.11.2.1 Philippines: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.11.3 Philippines: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.11.4 Philippines: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.12 Rest of Southeast Asia
10.3.6.6.12.1 Rest of Southeast Asia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.12.2 Rest of Southeast Asia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.12.2.1 Rest of Southeast Asia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.12.3 Rest of Southeast Asia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.12.4 Rest of Southeast Asia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.7 Rest of Asia Pacific
10.3.6.7.1 Overview
10.3.6.7.2 Rest of Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.7.3 Rest of Asia Pacific: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.7.3.1 Rest of Asia Pacific: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.7.4 Rest of Asia Pacific: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.7.5 Rest of Asia Pacific: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4 Middle East & Africa Lung Cancer Therapy Market, Revenue and Forecast to 2030
10.4.1 Overview
10.4.2 Middle East & Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.3 Middle East & Africa: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.3.1 Middle East & Africa: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.4 Middle East & Africa: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5 Middle East & Africa: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4.5.1 Middle East & Africa Lung Cancer Therapy Market, by Country
10.4.5.2 Saudi Arabia
10.4.5.2.1 Overview
10.4.5.2.2 Saudi Arabia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.2.3 Saudi Arabia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.2.3.1 Saudi Arabia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.5.2.4 Saudi Arabia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.2.5 Saudi Arabia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4.5.3 South Africa
10.4.5.3.1 Overview
10.4.5.3.2 South Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.3.3 South Africa: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.3.3.1 South Africa: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.5.3.4 South Africa: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.3.5 South Africa: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4.5.4 UAE
10.4.5.4.1 Overview
10.4.5.4.2 UAE Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.4.3 UAE: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.4.3.1 UAE: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.5.4.4 UAE: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.4.5 UAE: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4.5.5 Rest of Middle East Africa
10.4.5.5.1 Overview
10.4.5.5.2 Rest of Middle East Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.5.3 Rest of Middle East Africa: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.5.3.1 Rest of Middle East Africa: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.5.5.4 Rest of Middle East Africa: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.5.5 Rest of Middle East Africa: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.5 South & Central America Lung Cancer Therapy Market, Revenue and Forecast to 2030
10.5.1 Overview
10.5.2 South & Central America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.3 South & Central America: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.5.3.1 South & Central America: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.5.4 South & Central America: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.5.5 South & Central America: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.5.6 South & Central America Lung Cancer Therapy Market, by Country
10.5.6.1 Brazil
10.5.6.1.1 Overview
10.5.6.1.2 Brazil Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.1.3 Brazil: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.5.6.1.3.1 Brazil: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.5.6.1.4 Brazil: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.5.6.1.5 Brazil: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.5.6.2 Argentina
10.5.6.2.1 Overview
10.5.6.2.2 Argentina Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.2.3 Argentina: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.5.6.2.3.1 Argentina: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.5.6.2.4 Argentina: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.5.6.2.5 Argentina: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.5.6.3 Rest of South & Central America
10.5.6.3.1 Overview
10.5.6.3.2 Rest of South & Central America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.3.3 Rest of South & Central America: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.5.6.3.3.1 Rest of South & Central America: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.5.6.3.4 Rest of South & Central America: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.5.6.3.5 Rest of South & Central America: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
11. LUNG CANCER THERAPY MARKET – INDUSTRY LANDSCAPE
11.1 Overview
11.2 Growth Strategies in Lung Cancer Therapy Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. COMPANY PROFILES
12.1 Medtronic Plc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 RF Medical Co Ltd
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Johnson & Johnson
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Merck KGaA
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Sun Pharmaceutical Industries Ltd
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Bioventus Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Olympus Corp
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Meiji Seika Pharma Co Ltd
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Advanz Pharma Corp
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. APPENDIX
13.1 About Us
13.2 Glossary of Terms
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Lung Cancer Therapy Market, by Geography
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. LUNG CANCER THERAPY MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.2.1 Global PEST Analysis
5. LUNG CANCER THERAPY MARKET - KEY INDUSTRY DYNAMICS
5.1 Market Drivers:
5.1.1 Increase in Cases of Lung Cancer
5.1.2 Government Initiatives for Screening and Treatment of Lung Cancer
5.2 Market Restraints
5.2.1 High Cost of Lung Cancer Therapy
5.3 Market Opportunities
5.3.1 Rising Number of Lung Cancer Therapy in Clinical Trials
5.4 Future Trends
5.4.1 Growing Demand for Targeted Therapy
5.5 Impact Analysis:
6. LUNG CANCER THERAPY MARKET - GLOBAL MARKET ANALYSIS
6.1 Lung Cancer Therapy Market Revenue (US$ Mn), 2020 – 2030
7. GLOBAL LUNG CANCER THERAPY MARKET – REVENUE AND FORECAST TO 2030 – BY THERAPY TYPE
7.1 Overview
7.2 Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
7.3 Non-Invasive Therapy
7.3.1 Overview
7.3.2 Non-Invasive Therapy: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Minimally Invasive
7.4.1 Overview
7.4.2 Minimally Invasive: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
7.4.2.1 Global: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
8. GLOBAL LUNG CANCER THERAPY MARKET – REVENUE AND FORECAST TO 2030 – BY INDICATION
8.1 Overview
8.2 Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Non-Small Cell Lung Cancer
8.3.1 Overview
8.3.2 Non-Small Cell Lung Cancer: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Small Cell Lung Cancer
8.4.1 Overview
8.4.2 Small Cell Lung Cancer: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9. GLOBAL LUNG CANCER THERAPY MARKET – REVENUE AND FORECAST TO 2030 – BY END USER
9.1 Overview
9.2 Lung Cancer Therapy Market Revenue Share, by End User, 2022 & 2030 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Oncology Clinics
9.4.1 Overview
9.4.2 Oncology Clinics: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Research Centers
9.5.1 Overview
9.5.2 Research Centers: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
10. LUNG CANCER THERAPY MARKET - GEOGRAPHICAL ANALYSIS
10.1 North America Lung Cancer Therapy Market, Revenue and Forecast To 2030
10.1.1 Overview
10.1.2 North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.3 North America: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.3.1 North America: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.1.4 North America: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.5 North America: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.1.6 North America Lung Cancer Therapy Market, by Country
10.1.6.1 US
10.1.6.1.1 Overview
10.1.6.1.2 US Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.1.3 US: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.6.1.3.1 US: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.1.6.1.4 US: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.6.1.5 US: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.1.6.2 Canada
10.1.6.2.1 Overview
10.1.6.2.2 Canada Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.2.3 Canada: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.6.2.3.1 Canada: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.1.6.2.4 Canada: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.6.2.5 Canada: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.1.6.3 Mexico
10.1.6.3.1 Overview
10.1.6.3.2 Mexico Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.3.3 Mexico: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.6.3.3.1 Mexico: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.1.6.3.4 Mexico: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.6.3.5 Mexico: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2 Europe Lung Cancer Therapy Market, Revenue and Forecast to 2030
10.2.1 Overview
10.2.2 Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.3 Europe: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.3.1 Europe: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.4 Europe: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.5 Europe: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6 Europe Lung Cancer Therapy Market, by Country
10.2.6.1 UK
10.2.6.1.1 Overview
10.2.6.1.2 UK Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.1.3 UK: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.1.3.1 UK: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.1.4 UK: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.1.5 UK: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.2 Germany
10.2.6.2.1 Overview
10.2.6.2.2 Germany Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.2.3 Germany: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.2.3.1 Germany: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.2.4 Germany: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.2.5 Germany: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.3 France
10.2.6.3.1 Overview
10.2.6.3.2 France Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.3.3 France: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.3.3.1 France: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.3.4 France: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.3.5 France: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.4 Italy
10.2.6.4.1 Overview
10.2.6.4.2 Italy Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.4.3 Italy: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.4.3.1 Italy: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.4.4 Italy: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.4.5 Italy: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.5 Spain
10.2.6.5.1 Overview
10.2.6.5.2 Spain Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.5.3 Spain: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.5.3.1 Spain: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.5.4 Spain: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.5.5 Spain: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.6 Russia
10.2.6.6.1 Overview
10.2.6.6.2 Russia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.6.3 Russia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.6.3.1 Russia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.6.4 Russia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.6.5 Russia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.7 Rest of Europe
10.2.6.7.1 Overview
10.2.6.7.2 Rest of Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.7.3 Rest of Europe: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.7.3.1 Rest of Europe: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.7.4 Rest of Europe: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.7.5 Rest of Europe: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3 Asia Pacific Lung Cancer Therapy Market, Revenue and Forecast to 2030
10.3.1 Overview
10.3.2 Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.3 Asia Pacific: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.3.1 Asia Pacific: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.4 Asia Pacific: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.5 Asia Pacific: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6 Asia Pacific Lung Cancer Therapy Market, by Country
10.3.6.1 China
10.3.6.1.1 Overview
10.3.6.1.2 China Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.1.3 China: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.1.3.1 China: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.1.4 China: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.1.5 China: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.2 Japan
10.3.6.2.1 Overview
10.3.6.2.2 Japan Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.2.3 Japan: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.2.3.1 Japan: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.2.4 Japan: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.2.5 Japan: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.3 India
10.3.6.3.1 Overview
10.3.6.3.2 India Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.3.3 India: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.3.3.1 India: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.3.4 India: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.3.5 India: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.4 Australia
10.3.6.4.1 Overview
10.3.6.4.2 Australia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.4.3 Australia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.4.3.1 Australia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.4.4 Australia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.4.5 Australia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.5 South Korea
10.3.6.5.1 Overview
10.3.6.5.2 South Korea Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.5.3 South Korea: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.5.3.1 South Korea: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.5.4 South Korea: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.5.5 South Korea: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6 Southeast Asia
10.3.6.6.1 Overview
10.3.6.6.2 Southeast Asia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.3 Southeast Asia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.3.1 Southeast Asia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.4 Southeast Asia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.5 Southeast Asia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.6 Singapore
10.3.6.6.6.1 Singapore Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.6.2 Singapore: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.6.2.1 Singapore: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.6.3 Singapore: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.6.4 Singapore: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.7 Malaysia
10.3.6.6.7.1 Malaysia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.7.2 Malaysia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.7.2.1 Malaysia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.7.3 Malaysia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.7.4 Malaysia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.8 Indonesia
10.3.6.6.8.1 Indonesia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.8.2 Indonesia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.8.2.1 Indonesia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.8.3 Indonesia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.8.4 Indonesia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.9 Vietnam
10.3.6.6.9.1 Vietnam Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.9.2 Vietnam: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.9.2.1 Vietnam: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.9.3 Vietnam: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.9.4 Vietnam: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.10 Cambodia
10.3.6.6.10.1 Cambodia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.10.2 Cambodia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.10.2.1 Cambodia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.10.3 Cambodia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.10.4 Cambodia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.11 Philippines
10.3.6.6.11.1 Philippines Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.11.2 Philippines: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.11.2.1 Philippines: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.11.3 Philippines: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.11.4 Philippines: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.12 Rest of Southeast Asia
10.3.6.6.12.1 Rest of Southeast Asia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.12.2 Rest of Southeast Asia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.12.2.1 Rest of Southeast Asia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.12.3 Rest of Southeast Asia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.12.4 Rest of Southeast Asia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.7 Rest of Asia Pacific
10.3.6.7.1 Overview
10.3.6.7.2 Rest of Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.7.3 Rest of Asia Pacific: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.7.3.1 Rest of Asia Pacific: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.7.4 Rest of Asia Pacific: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.7.5 Rest of Asia Pacific: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4 Middle East & Africa Lung Cancer Therapy Market, Revenue and Forecast to 2030
10.4.1 Overview
10.4.2 Middle East & Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.3 Middle East & Africa: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.3.1 Middle East & Africa: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.4 Middle East & Africa: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5 Middle East & Africa: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4.5.1 Middle East & Africa Lung Cancer Therapy Market, by Country
10.4.5.2 Saudi Arabia
10.4.5.2.1 Overview
10.4.5.2.2 Saudi Arabia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.2.3 Saudi Arabia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.2.3.1 Saudi Arabia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.5.2.4 Saudi Arabia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.2.5 Saudi Arabia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4.5.3 South Africa
10.4.5.3.1 Overview
10.4.5.3.2 South Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.3.3 South Africa: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.3.3.1 South Africa: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.5.3.4 South Africa: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.3.5 South Africa: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4.5.4 UAE
10.4.5.4.1 Overview
10.4.5.4.2 UAE Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.4.3 UAE: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.4.3.1 UAE: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.5.4.4 UAE: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.4.5 UAE: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4.5.5 Rest of Middle East Africa
10.4.5.5.1 Overview
10.4.5.5.2 Rest of Middle East Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.5.3 Rest of Middle East Africa: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.5.3.1 Rest of Middle East Africa: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.5.5.4 Rest of Middle East Africa: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.5.5 Rest of Middle East Africa: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.5 South & Central America Lung Cancer Therapy Market, Revenue and Forecast to 2030
10.5.1 Overview
10.5.2 South & Central America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.3 South & Central America: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.5.3.1 South & Central America: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.5.4 South & Central America: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.5.5 South & Central America: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.5.6 South & Central America Lung Cancer Therapy Market, by Country
10.5.6.1 Brazil
10.5.6.1.1 Overview
10.5.6.1.2 Brazil Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.1.3 Brazil: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.5.6.1.3.1 Brazil: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.5.6.1.4 Brazil: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.5.6.1.5 Brazil: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.5.6.2 Argentina
10.5.6.2.1 Overview
10.5.6.2.2 Argentina Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.2.3 Argentina: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.5.6.2.3.1 Argentina: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.5.6.2.4 Argentina: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.5.6.2.5 Argentina: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.5.6.3 Rest of South & Central America
10.5.6.3.1 Overview
10.5.6.3.2 Rest of South & Central America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.3.3 Rest of South & Central America: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.5.6.3.3.1 Rest of South & Central America: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.5.6.3.4 Rest of South & Central America: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.5.6.3.5 Rest of South & Central America: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
11. LUNG CANCER THERAPY MARKET – INDUSTRY LANDSCAPE
11.1 Overview
11.2 Growth Strategies in Lung Cancer Therapy Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. COMPANY PROFILES
12.1 Medtronic Plc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 RF Medical Co Ltd
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Johnson & Johnson
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Merck KGaA
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Sun Pharmaceutical Industries Ltd
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Bioventus Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Olympus Corp
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Meiji Seika Pharma Co Ltd
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Advanz Pharma Corp
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. APPENDIX
13.1 About Us
13.2 Glossary of Terms
